CC BY 4.0 · Thromb Haemost 2020; 120(01): 027-035
DOI: 10.1055/s-0039-1695771
Coagulation and Fibrinolysis
Georg Thieme Verlag KG Stuttgart · New York

Global Use of Idarucizumab in Clinical Practice: Outcomes of the RE-VECTO Surveillance Program

John Fanikos
1   Brigham and Women's Hospital, Boston, Massachusetts, United States
,
Debra Murwin
2   Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut, United States
,
Fredrik Gruenenfelder
3   Boehringer Ingelheim International GmbH, Ingelheim, Germany
,
Igor Tartakovsky
3   Boehringer Ingelheim International GmbH, Ingelheim, Germany
,
Lionel Riou França
3   Boehringer Ingelheim International GmbH, Ingelheim, Germany
,
Paul A. Reilly
2   Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut, United States
,
Pawel Kermer
4   Department of Neurology, Nordwest-Krankenhaus Sanderbusch, Sande, Germany
5   University Medical Center Göttingen, Göttingen, Germany
,
Fredrik von Wowern
6   University Hospitals of Skåne – Malmö, Skåne, Sweden
,
Deirdre A. Lane
7   Liverpool Centre for Cardiovascular Science, Liverpool Heart and Chest Hospital, University of Liverpool, Liverpool, United Kingdom
,
Ken Butcher
8   Prince of Wales Clinical School, University of New South Wales, Sydney, Australia
9   Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
› Author Affiliations
Funding The RE-VECTO surveillance program was funded by Boehringer Ingelheim Pharma GmbH & Co. KG.
Further Information

Publication History

28 March 2019

19 July 2019

Publication Date:
30 August 2019 (online)

Abstract

Idarucizumab was approved for the reversal of dabigatran in 2015. We investigated whether postapproval usage patterns of idarucizumab in a real-world setting reflect those observed in the pivotal trials. No safety or efficacy data were collected in this medical record-based observational study. RE-VECTO, a global postapproval, international, surveillance program, involved hospital pharmacies in countries where idarucizumab was licensed and dispensed (August 2016–June 2018). Characteristics of sites prescribing idarucizumab and of eligible patients (≥ 18 years old and receiving idarucizumab regardless of prior oral anticoagulant use), as well as idarucizumab utilization data, were collected and analyzed descriptively. Sixty-one sites enrolled 359 patients. Most pharmacies (85.2%) were centralized, and the median idarucizumab units stocked per hospital was 2.0 (interquartile range, 1.0–3.0). Almost three-quarters of patients were elderly (74.9% aged > 70 years), and only four (1.1%) had received idarucizumab before. Nearly all patients were treated with dabigatran (97.5%). There was a low frequency of unapproved dabigatran dosage regimens (3.3%). Life-threatening or uncontrolled bleeding was the most frequent indication for idarucizumab (57.7%), followed by emergency surgery/urgent procedure (35.9%). Of the life-threatening bleeding events, the most frequent were gastrointestinal tract (44.4%) and intracranial (38.6%). Most patients (95.0%) were given the full dose of two vials (2 × 2.5 g) of idarucizumab initially, and very few (1.7%) received a second dose. Of those patients requiring emergency or scheduled/planned surgery/procedures, 25.5% underwent gastrointestinal and/or abdominal surgery/procedures. Real-world usage patterns of idarucizumab provide valuable insights into emergency reversal strategies. Off-label use was minimal.

Authors' Contributions

All authors were involved with designing the surveillance program, provided critical review of the article, and approved the final version for publication.


 
  • References

  • 1 Greinacher A, Thiele T, Selleng K. Reversal of anticoagulants: an overview of current developments. Thromb Haemost 2015; 113 (05) 931-942
  • 2 Das A, Liu D. Novel antidotes for target specific oral anticoagulants. Exp Hematol Oncol 2015; 4: 25
  • 3 Kirchhof P, Benussi S, Kotecha D. , et al; ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37 (38) 2893-2962
  • 4 Macle L, Cairns J, Leblanc K. , et al; CCS Atrial Fibrillation Guidelines Committee. 2016 Focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation. Can J Cardiol 2016; 32 (10) 1170-1185
  • 5 European Medicines Agency. 2015 . Idarucizumab summary of product characteristics. Available at: https://www.ema.europa.eu/documents/product-information/praxbind-epar-product-information_en.pdf . Accessed October 10, 2018
  • 6 US Food and Drug Administration. 2015 . Idarucizumab prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761025lbl.pdf . Accessed October 10, 2018
  • 7 US Food and Drug Administration. 2018 . Andexanet alfa prescribing information. Available at: https://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM606687.pdf . Accessed October 10, 2018
  • 8 Eikelboom JW, Quinlan DJ, van Ryn J, Weitz JI. Idarucizumab: the antidote for reversal of dabigatran. Circulation 2015; 132 (25) 2412-2422
  • 9 Schiele F, van Ryn J, Canada K. , et al. A specific antidote for dabigatran: functional and structural characterization. Blood 2013; 121 (18) 3554-3562
  • 10 Pollack Jr CV, Reilly PA, van Ryn J. , et al. Idarucizumab for dabigatran reversal - full cohort analysis. N Engl J Med 2017; 377 (05) 431-441
  • 11 European Medicines Agency. Dabigatran etexilate. Summary of Product Characteristics. Available at: https://www.ema.europa.eu/documents/product-information/pradaxa-epar-product-information_en.pdf . Accessed October 10, 2018
  • 12 US Food and Drug Administration. Dabigatran etexilate prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022512s035lbl.pdf . Accessed October 10, 2018
  • 13 Pollack Jr CV, Reilly PA, Eikelboom J. , et al. Idarucizumab for dabigatran reversal. N Engl J Med 2015; 373 (06) 511-520
  • 14 Glund S, Stangier J, Schmohl M. , et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet 2015; 386 (9994): 680-690
  • 15 van Ryn J, Yasaka M, Ikushima I. , et al. Idarucizumab, a specific reversal agent for dabigatran: immediate, complete and sustained reversal of dabigatran-induced anticoagulation in Japanese healthy male volunteers. Blood 2016; 128 (Suppl. 22) 2627
  • 16 Glund S, Stangier J, van Ryn J. , et al. Effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase Ib study. Clin Pharmacokinet 2017; 56 (01) 41-54
  • 17 Glund S, Stangier J, Schmohl M. , et al. Idarucizumab, a specific antidote for dabigatran: immediate, complete and sustained reversal of dabigatran induced anticoagulation in elderly and renally impaired subjects. Blood 2014; 124 (Suppl. 21) 344
  • 18 Fang CW, Tsai YT, Chou PC. , et al. Intravenous thrombolysis in acute ischemic stroke after idarucizumab reversal of dabigatran effect: analysis of the cases from Taiwan. J Stroke Cerebrovasc Dis 2019; 28 (03) 815-820
  • 19 Kermer P, Eschenfelder CC, Diener HC. , et al. Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany - a national case collection. Int J Stroke 2017; 12 (04) 383-391
  • 20 van der Wall SJ, van Rein N, van den Bemt B. , et al. Performance of idarucizumab as antidote of dabigatran in daily clinical practice. Europace 2019; 21 (03) 414-420
  • 21 Connolly SJ, Milling Jr TJ, Eikelboom JW. , et al; ANNEXA-4 Investigators. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 2016; 375 (12) 1131-1141
  • 22 Siegal DM, Curnutte JT, Connolly SJ. , et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 2015; 373 (25) 2413-2424
  • 23 Martin K, Bégaud B, Latry P, Miremont-Salamé G, Fourrier A, Moore N. Differences between clinical trials and postmarketing use. Br J Clin Pharmacol 2004; 57 (01) 86-92